Helicobacter pylori vaccines: Is DNA the answer?

Helicobacter

Volumn 11, Issue 6, 2006, Pages 513-516

  Emancipator, Douglas ^a   Nedrud, John G ^a   Czinn, Steven J ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL ANTIGEN; CATALASE; CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; EXOTOXIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN A; HEAT SHOCK PROTEIN B; HELICOBACTER PYLORI VACCINE; IMMUNOLOGICAL ADJUVANT; UNCLASSIFIED DRUG; UREASE; UREASE B;

ANTIBIOTIC RESISTANCE; CANCER RISK; CELLULAR IMMUNITY; DIARRHEA; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; NAUSEA; NONHUMAN; PEPTIC ULCER; PLASMID; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH CANCER; STOMACH CARCINOGENESIS; TREATMENT FAILURE; VACCINATION;

ANIMALS; BACTERIAL VACCINES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; UREASE; VACCINATION; VACCINES, DNA;

HELICOBACTER PYLORI;

EID: 33750538438     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2006.00452.x     Document Type: Editorial

References (34)

1. Marshall BJ, McGechie DB, Francis GJ, Utley PJ. Pyloric campylobacter serology. Lancet 1984;ii:281.
2. The EUROGAST Study Group. Epidemiology of, and risk factors for, Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations. Gut 1993;34:1672-6.
3. Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rappuoli R. Helicobacter pylori virulence and genetic geography. Science 1999;284:1328-33.
4. Unge P. What other regimens are under investigation to treat Helicobacter pylori infection? Gastroenterology 1997;113:S131-48.
5. Borody TJ, Carrick J, Hazell SL. Symptoms improve after the eradication of gastric Campylobacter pyloridis. Med J Aust 1987;146:450-1.
6. Dubois A, Berg DE, Incecik ET, Fiala N, Heman-Ackah LM, Del Valle J, Yang M, Wirth HP, Perez-Perez GI, Blaser MJ. Host specificity of Helicobacter pylori strains and host responses in experimentally challenged nonhuman primates. Gastroenterology 1999;116:90-6.
7. Batchelder M, Fox J, Hayward A, Yan L, Shames B, Murphy J, Palley L. Natural and experimental Helicobacter mustelae reinfection following successful antimicrobial eradication in ferrets. Helicobacter 1996;1:34-42.
8. Czinn SJ, Bierman JC, Diters RW, Blanchard TJ, Leunk RD. Characterization and therapy for experimental infection by Helicobacter mustelae in ferrets. Helicobacter 1996;1:43-51.
9. Corthesy-Theulaz I, Porta N, Glauser M, Saraga E, Vaney A-C, Haas R, Kraehenbuhl JP, Blum AL, Michetti P. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology 1995;109:115-21.
10. Sutton P, Wilson J, Kosaka T, Wolowczuk I, Lee A. Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies. Immunol Cell Biol 2000;78:28-30.
11. Lee CK. Vaccination against Helicobacter pylori in non-human primate models and humans. Scand J Immunol 2001;53:437-42.
12. Eaton KA. Animal models of Helicobacter gastritis. In: Westblom TU, Czinn SJ, Nedrud JG, eds. Gastroduodenal Disease, Helicobacter pylori. Berlin: Springer-Verlag, 1999;241:123-54.
13. Nedrud JG. Helicobacter pylori vaccines: lessons from small animal models. Scand J Immunol 2001;53:429-36.
14. Solnick JV, Schauer DB. Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases. Clin Microbiol Rev 2001;14:59-97.
15. Crabtree JE, Court M, Aboshkiwa MA, Jeremy AH, Dixon MF, Robinson PA. Gastric mucosal cytokine and epithelial cell responses to Helicobacter pylori infection in Mongolian gerbils. J Pathol 2004;202:197-207.
16. Sutton P. Progress in vaccination against Helicobacter pylori. Vaccine 2001;19:2286-90.
17. Del Giudice G, Covacci A, Telford JL, Montecucco C, Rappuoli R. The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol 2001;19:523-63.
18. Svennerholm AM. Prospects for a mucosally-administered vaccine against Helicobacter pylori. Vaccine 2003;21:347-53.
19. Blanchard TG, Eisenberg JC, Matsumoto Y. Clearance of Helicobacter pylori infection through immunization: the site of T cell activation contributes to vaccine efficacy. Vaccine 2004;22:888-97.
20. Garhart CA, Redline RW, Nedrud JG, Czinn SJ. Clearance of Helicobacter pylori infection and resolution of post immunization gastritis in a kinetic study of prophylactically immunized mice. Infect Immun 2002;70:3529-38.
21. Dzwonek A, Mikula M, Woszczynski M, Hennig E, Ostrowski J. Protective effect of vaccination with DNA of the H. pylori genomic library in experimentally infected mice. Cell Mol Biol Lett 2004;9:483-95.
22. Michetti P, Kreiss C, Kotloff KL, et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori -infected adults. Gastroenterology 1999;116:804-12.
23. Hatzifoti C, Roussel Y, Harris AG, Wren BW, Morrow JW, Bajaj-Elliott M. Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori. Helicobacter 2006;11:113-22.
24. Ermak TH, Giannasca PJ, Nichols R, Myers GA, Nedrud JG, Lee CK, Weltzin R, Kleanthous H, Monath TP. MHC-class II but not MHC-class I or B cell responses are required for vaccine-induced protection against murine Helicobacter pylori infection. Abstracts to Third International Workshop on Pathogenesis and Host Response in Helicozbcter Infections, Helsingor, Denmark 1998.
25. Akhiani AA, Pappo J, Kabok Z, Schon K, Gao W, Franzen LE, Lycke N. Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 Cells. J Immunol 2002;169:6977-84.
26. Garhart CA, Heinzel FP, Czinn SJ, Nedrud JG. Vaccine-induced reduction of Helicobacter pylori colonization in mice is interleukin-12 dependent but gamma interferon and inducible nitric oxide synthase independent. Infect Immun 2003;71:910-21.
27. Johnston SA, Barry MA. Genetic to genomic vaccination. Vaccine 1997;15:808-9.
28. Gomis S, Babiuk L, Godson DL, Allan B, Thrush T, Townsend H, Willson P, Waters E, Hecker R, Potter A. Protection of chickens against Escherichia coli infections by DNA containing CpG motifs. Infect Immun 2003;71:857-63.
29. Ioannou XP, Gomis SM, Hecker R, Babiuk LA, van Drunen Littelvan den Hurk S. Safety and efficacy of CpG-containing oligodeoxynucleotides as immunological adjuvants in rabbits. Vaccine 2003;21:4368-72.
30. Mapletoft JW, Oumouna M, Townsend HG, Gomis S, Babiuk LA, van Drunen Littel-van den Hurk S. Formulation with CpG oligodeoxynucleotides increases cellular immunity and protection induced by vaccination of calves with formalin-inactivated bovine respiratory syncytial virus. Virology 2006.
31. Gomis S, Babiuk L, Allan B, Willson P, Waters E, Ambrose N, Hecker R, Potter A. Protection of neonatal chicks against a lethal challenge of Escherichia coli using DNA containing cytosine-phosphodiester-guanine motifs. Avian Dis 2004;48:813-22.
32. Todoroki I, Joh T, Watanabe K, Miyashita M, Seno K, Nomura T, Ohara H, Yokoyama Y, Tochikubo K, Itoh M. Suppressive effects of DNA vaccines encoding heat shock protein on Helicobacter pylori-induced gastritis in mice. Biochem Biophys Res Commun 2000;277:159-63.
33. Miyashita M, Joh T, Watanabe K, et al. Immune responses in mice to intranasal and intracutaneous administration of a DNA vaccine encoding Helicobacter pylori-catalase. Vaccine 2002;20:2336-42.
34. Kennedy RC, Shearer MH, Hildebrand W. Nonhuman primate models to evaluate vaccine safety and immunogenicity. Vaccine 1997;15:903-8.